Approval · Notice of Compliance 10612 · 2009
ABLAVAR: Notice of Compliance 10612
Issued September 24, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10612
- Date
- September 24, 2009
- Company
- Lantheus Mi Canada IncMontreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Intravenous Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABLAVAR | Not yet assigned | — |
Medicinal ingredients
- GADOFOSVESET TRISODIUM 244 MG per ML